Synaptogenix inc
WebNov 18, 2024 · Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced ... WebSynaptogenix, Inc. 78 followers on LinkedIn. Clinical-stage biopharmaceutical company working to develop novel therapies for neurodegenerative diseases Synaptogenix is a clinical-stage ...
Synaptogenix inc
Did you know?
WebSNPX Synaptogenix Inc Current Report Filing (8-k) 0001571934 false 0001571934 2024-04-14 2024-04-14 iso4217:USD xbrli:shares ... WebSynaptogenix, Inc. 1185 Avenue of the Americas 3rd Floor New York, NY 10036. IR Contact T: 800-811-5591 [email protected]
WebApr 6, 2024 · Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 … WebSep 28, 2024 · Post # of 21285. Does anyone know the minimum share price for the Preferred Shareholders to be paid back in shares versus cash?? I believe it was $1.50, but the current version has me a little confused. The $1.50 became a $1.25 but there is an alternative value, does anyone understand what this is in a practical sense?? It's bold of …
WebSynaptogenix, Inc. 1185 Avenue of the Americas 3rd Floor New York, NY 10036. IR Contact T: 800-811-5591 [email protected] WebSynaptogenix, Inc. Daily – Vickers Top Buyers & Sellers for 01/03/2024 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider …
WebSynaptogenix, Inc. (Exact name of registrant as specified in its charter) Delaware: 001-40458: 46-1585656 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1185 Avenue of the Americas, 3 …
WebJul 20, 2024 · NEW YORK, July 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today, in preparation for its next phase of Bryostatin clinical development, the dosing of its first patient in the … under ground gas tank capWebGet the latest Synaptogenix Inc (SNPX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. underground gas storage mapWebGet the latest Synaptogenix Inc (SNPX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment … underground gas storage tankWebApr 7, 2024 · Synaptogenix Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-1.580 per share for the current fiscal year. Synaptogenix Inc does not currently pay a dividend. The Biotechnology and Medical Research sub-industry … underground gate automation kitWebApr 10, 2024 · Synaptogenix Inc’s price-to-book ratio is higher than its peers. This could make Synaptogenix Inc less attractive for value investors when compared to the industry median at 1.40. You can read more about Synaptogenix Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its … thoughtclan technologiesWebSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative … underground gas pipe locatorWebSynaptogenix, Inc. is a biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X … thought clan